Prostate Cancer — Written Clinical Reasoning · Phys Written Answers

Prompt

DCE-style written reasoning for Prostate Cancer.

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Prostate Cancer and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Tatarano S, Mitsuke A, Osako Y, Sakaguchi T, et al. NTRK fusion in metastatic castration-resistant prostate cancer treated with entrectinib: a case report J Med Case Rep, 2026.PMID 42469872
[2]Akinnola OO, Olaniyan AI, Adeboye BA, Akinyosoye AD Impact of immunotherapy as a monotherapy or in combination with conventional therapies on regulatory T-cell (Treg) modulation in prostate cancer: a systematic review BMC Cancer, 2026.PMID 42469702
[3]Watfa M, Dortche K, Fervaha G, Younis SK, et al. Long-term oncologic outcomes of patients with grade group 1 prostate cancer and pT3a disease on final pathology Prostate Cancer Prostatic Dis, 2026.PMID 42469509
[4]Melchior F, Koett M, Aigner G, Schroffenegger J, et al. Real-World Use of Prolaris® to Guide Treatment Decisions in Localized Prostate Cancer Eligible for Active Surveillance Urol Int, 2026.PMID 42467602
[5]Aly M, Joseph A, Amer T The Evidence-Practice Gap in Testosterone Therapy for Prostate Cancer: A Narrative Review Cureus, 2026.PMID 42465160
[6]Buali HF, Al Shaibani A, Farouqi US, Abushloa T, et al. Prostate Cancer Screening: Current Controversies and Future Directions Cureus, 2026.PMID 42465149
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

Model Answer

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

SAQ 2 — Exam trap defence (8 marks)

Prompt: Name two high-yield traps in Prostate Cancer and how you avoid them. [1] [2]

Model Answer

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

References

[1]Tatarano S, Mitsuke A, Osako Y, Sakaguchi T, et al. NTRK fusion in metastatic castration-resistant prostate cancer treated with entrectinib: a case report J Med Case Rep, 2026.PMID 42469872
[2]Akinnola OO, Olaniyan AI, Adeboye BA, Akinyosoye AD Impact of immunotherapy as a monotherapy or in combination with conventional therapies on regulatory T-cell (Treg) modulation in prostate cancer: a systematic review BMC Cancer, 2026.PMID 42469702
[3]Watfa M, Dortche K, Fervaha G, Younis SK, et al. Long-term oncologic outcomes of patients with grade group 1 prostate cancer and pT3a disease on final pathology Prostate Cancer Prostatic Dis, 2026.PMID 42469509
[4]Melchior F, Koett M, Aigner G, Schroffenegger J, et al. Real-World Use of Prolaris® to Guide Treatment Decisions in Localized Prostate Cancer Eligible for Active Surveillance Urol Int, 2026.PMID 42467602
[5]Aly M, Joseph A, Amer T The Evidence-Practice Gap in Testosterone Therapy for Prostate Cancer: A Narrative Review Cureus, 2026.PMID 42465160
[6]Buali HF, Al Shaibani A, Farouqi US, Abushloa T, et al. Prostate Cancer Screening: Current Controversies and Future Directions Cureus, 2026.PMID 42465149
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922